PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice

@article{Kapoor2014PARPIO,
  title={PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice},
  author={Kunal Kapoor and Esha Singla and Bijayani Sahu and Amarjit S. Naura},
  journal={Molecular and Cellular Biochemistry},
  year={2014},
  volume={400},
  pages={153-162}
}
We have previously shown that PARP-1 inhibition provides protection against lung inflammation in the context of asthma and acute lung injury. Olaparib is a potent new generation PARP inhibitor that has been approved for human testing. The present work was designed to evaluate its beneficial potential against LPS-induced acute lung injury and acute kidney injury upon intratracheal administration of the endotoxin in mice. Administration of olaparib at different doses, 30 min after LPS treatment… CONTINUE READING